Technical Analysis for LNTH - Lantheus Holdings, Inc.

Grade Last Price % Change Price Change
C 69.48 -0.07% -0.05
LNTH closed down 0.07 percent on Friday, September 29, 2023, on 1.24 times normal volume. It ran into resistance at its 50 day moving average. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Up

Date Alert Name Type % Chg
50 DMA Resistance Bearish 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Multiple of Ten Bearish Other 0.00%
Gapped Up Strength 0.00%
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
Stochastic Reached Overbought Strength -0.07%
Multiple of Ten Bearish Other -0.07%
Above Upper BB Strength -0.07%
Overbought Stochastic Strength -0.07%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Rose Above Previous Day's High about 12 hours ago
50 DMA Resistance about 12 hours ago
Gap Up Closed about 13 hours ago
Gap Up Partially Closed about 13 hours ago
Down 1% about 13 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Lantheus Holdings, Inc. Description

Lantheus Holdings, Inc. is engaged in developing, manufacturing, selling and distributing diagnostic medical imaging agents and products that assist clinicians in the diagnosis of cardiovascular and other diseases. The Company's medical imaging agents are used to diagnose coronary artery disease, congestive heart failure, stroke, peripheral vascular disease and other diseases. The Company's products include contrast agents and medical radiopharmaceuticals, including technetium generators. The Company's products include DEFINITY, TechneLite, Xenon Xe 133 Gas, Cardiolite, Neurolite, Thallium Tl 201, Gallium Ga 67, Gludef, Quadramet and Ablavar. The Company is also engaged in developing agents, such as Flurpiridaz F 18, which is a myocardial perfusion imaging agent; 18F LMI 1195, which is a cardiac neuronal imaging agent, and LMI 1174, which is a vascular remodeling imaging agent.


Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Medicine Disease Chemical Elements Prostate Cancer Heart Failure Medical Imaging Stroke Medical Physics Perfusion Artery Radiopharmaceuticals Artery Disease Congestive Heart Failure Imaging Agent Peripheral Vascular Disease Coronary Artery Disease Gallium Neuron Cardiovascular And Other Diseases Medicinal Radiochemistry Myocardial Perfusion Imaging

Is LNTH a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 100.8505
52 Week Low 47.46
Average Volume 1,019,100
200-Day Moving Average 74.22
50-Day Moving Average 70.06
20-Day Moving Average 65.09
10-Day Moving Average 64.62
Average True Range 2.49
RSI (14) 57.98
ADX 28.7
+DI 29.56
-DI 19.96
Chandelier Exit (Long, 3 ATRs) 62.96
Chandelier Exit (Short, 3 ATRs) 67.33
Upper Bollinger Bands 69.77
Lower Bollinger Band 60.41
Percent B (%b) 0.97
BandWidth 14.37
MACD Line -0.74
MACD Signal Line -1.80
MACD Histogram 1.0636
Fundamentals Value
Market Cap 4.65 Billion
Num Shares 66.9 Million
EPS 0.01
Price-to-Earnings (P/E) Ratio 8685.00
Price-to-Sales 1.87
Price-to-Book 1.71
PEG Ratio 0.61
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 72.48
Resistance 3 (R3) 72.47 71.45 71.98
Resistance 2 (R2) 71.45 70.69 71.46 71.81
Resistance 1 (R1) 70.47 70.22 69.96 70.48 71.65
Pivot Point 69.45 69.45 69.20 69.46 69.45
Support 1 (S1) 68.47 68.69 67.96 68.48 67.31
Support 2 (S2) 67.45 68.22 67.46 67.15
Support 3 (S3) 66.47 67.45 66.98
Support 4 (S4) 66.48